AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
May 292013
 

 

3 Biopharma Runners With Fuel in the Tank
Investorplace.com
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97%

 

Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% response rate, with 93% of trial patients surviving progression-free at the end of two years. CLL, which produces too many mature white cells, is the second most common form of leukemia in the U.S.

http://investorplace.com/2013/05/3-biopharma-runners-with-fuel-in-the-tank/

Share

Researchers identify novel class of drugs for prostate cancers

 Uncategorized  Comments Off on Researchers identify novel class of drugs for prostate cancers
May 292013
 

Photo of Dr. Ganesh Raj, an associate professor of urology at UT Southwestern Medical Center.

http://www.sciencecodex.com/researchers_identify_novel_class_of_drugs_for_prostate_cancers-112935

(Photo Credit: UT Southwestern Medical Center)

Share

Omthera Fish-Oil Drug Hooks AstraZeneca in $323M Buyout

 drugs  Comments Off on Omthera Fish-Oil Drug Hooks AstraZeneca in $323M Buyout
May 292013
 

AstraZeneca plc’s planned buyout of Omthera Pharmaceuticals Inc. to gain Phase III-validated Epanova, the anti-triglyceride therapy based on ultra-pure fish oil, puts the firm at a “distinct commercial advantage” over Amarin Corp. plc, with its recently launched Vascepa (icosapent ethyl), said Decision Resources (DR) analyst Paramjit Narang.

http://www.bioworld.com/content/omthera-fish-oil-drug-hooks-astrazeneca-323m-buyout-0

Share

Bristol Myers Squibb Co.present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)

 Phase 3 drug  Comments Off on Bristol Myers Squibb Co.present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)
May 292013
 

Bristol Myers Squibb Co. (BMY), Gilead Sciences, Inc. (GILD), Halozyme
Insider Monkey (blog)
present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.) Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co.

http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-gilead-sciences-inc-gild-halozyme-therapeutics-inc-halo-3-stocks-to-watch-ahead-of-asco-152583/

 

Bristol Myers Squibb Co. (NYSE:BMY) present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)

Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co. (NYSE:BMY) will be presenting data for a Phase 1 study of nivolumad combined with Yervoy to treat melanoma. In a 52-patient study, patients with advanced melanoma saw an overall tumor shrinkage rate of 40%.

However, the company’s most advanced study with nivolumab is in treating advanced non-small cell lung cancer. There, it produced an overall survival of 9.6 months, which is 30% better than standard-of-care. It’s also produced a 22-month overall survival rate in patients with advanced kidney cancer; compared to 20 months for the current standard of care

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: